GlassScriptPhysician profile
Majed M Samarneh
NPI 1366687139
$1,400.51
in general payments reported to CMS, 2019-2025
16 companies · $56.05 in 2025
The $56.05 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $208 · 2021: $184 · 2022: $56.49 · 2023: $133 · 2024: $477 · 2025: $56.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $665.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $411.67 | 2019-2024 | Repatha |
| Otsuka America Pharmaceutical, INC. | $125.38 | 2020-2024 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.57 | 2019 | |
| Novartis Pharmaceuticals Corporation | $106.52 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $104.66 | 2020-2024 | Acthar |
| Glaxosmithkline, LLC. | $98.73 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.22 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $83.29 | 2023-2024 | Lupkynis |
| Vifor Pharma, INC. | $60.68 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $57.72 | 2019 | |
| Ardelyx, INC. | $49.83 | 2024-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $28.86 | 2023 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $21.97 | 2021 | |
| Fresenius USA Marketing, INC. | $16.65 | 2019 | |
| Travere Therapeutics, INC. | $16.49 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strongbridge US INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Majed Samarneh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.